Rekombinanter Podoplanin Antikörper

Produktnummer ABIN7127674

Produktdetails anti-Podoplanin Antikörper

Target: Podoplanin (PDPN)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser Podoplanin Antikörper ist unkonjugiert

Applikation: ELISA

Kreuzreaktivität: Human

Aufreinigung: Affinity-chromatography

Immunogen: A synthesized peptide derived from human PDPN

Klon: 4E6

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu Podoplanin

Target: Podoplanin (PDPN)

Andere Bezeichnung: PDPN (PDPN Produkte)

Synonyme: PDPN antikoerper, AGGRUS antikoerper, GP36 antikoerper, GP40 antikoerper, Gp38 antikoerper, HT1A-1 antikoerper, OTS8 antikoerper, PA2.26 antikoerper, T1A antikoerper, T1A-2 antikoerper, OTS-8 antikoerper, RANDAM-2 antikoerper, T1-alpha antikoerper, T1a antikoerper, T1alpha antikoerper, E11 antikoerper, RTI40 antikoerper, podoplanin antikoerper, PDPN antikoerper, Pdpn antikoerper

Hintergrund:

Background: Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation (PubMed:14522983, PubMed:15231832, PubMed:17616532, PubMed:18215137, PubMed:17222411). Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN (PubMed:18541721). Through MSN or EZR interaction promotes epithelial-mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness (PubMed:17046996, PubMed:21376833). Interaction with CD44 promotes directional cell migration in epithelial and tumor cells (PubMed:20962267). In lymph nodes (LNs), controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR, MSN and RDX) and MYL9 activation through association with unknown transmembrane proteins. Engagement of CLEC1B by PDPN promotes FRCs relaxation by blocking lateral membrane interactions leading to reduction of ERM proteins (EZR, MSN and RDX) and MYL9 activation (By similarity). Through binding with LGALS8 may participate to connection of the lymphatic endothelium to the surrounding extracellular matrix (PubMed:19268462). In keratinocytes, induces changes in cell morphology showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion (PubMed:15515019). Controls invadopodia stability and maturation leading to efficient degradation of the extracellular matrix (ECM) in tumor cells through modulation of RHOC activity in order to activate ROCK1/ROCK2 and LIMK1/LIMK2 and inactivation of CFL1 (PubMed:25486435). Required for normal lung cell proliferation and alveolus formation at birth (By similarity). Does not function as a water channel or as a regulator of aquaporin-type water channels (PubMed:9651190). Does not have any effect on folic acid or amino acid transport (By similarity).

Aliases: Podoplanin, Aggrus, PDPN

UniProt: Q86YL7

Pathways: Dicarboxylic Acid Transport